Listing added: August 22, 2012 2:27 pm
Sales increase of 3.3 million compared to last year period ? EBIT declines to 1.29 million Euros ? Gratifying growth in the Middle East and in Asia
Jena, August 22nd, 2012 ? biolitec AG (ISIN DE0005213409), Jena, listed on the Prime Standard of the Frankfurt Stock Exchange, achieved group sales of 29.4 million Euros in the first three quarters of the 2011/12 fiscal year. Thus, sales increased by approximately 3.3 million Euros compared to the same period in the previous fiscal year. The growth in sales is attributable to the steadily rising demand for biolitec treatments; for example, for the benign prostate hyperplasia (LIFE?), the endoluminal laser treatment for veins (ELVeS?) and the new HeLP? (Haemorrhoid Laser Procedure) treatment for the atrophy of haemorrhoidal arteries.
Expenses relating to Research & Development for the first three quarters of the 2011/12 fiscal year for an amount of 3.18 million Euros (approximately 10.8% of sales) reached the previous year?s level. The sales and marketing expensed have increased to 9.13 million Euros (compared to 8.04 million Euros in the same period of the previous year).
The gross profit of 18.56 million Euros has remained at the level of the previous year (previous year: 18.59 million Euros) and the Earnings Before Interest and Tax (EBIT) declined to 1.29 million Euros (previous year: 1.49 million Euros).
Significant revenues of biolitec AG were achieved in Europe and North America. With 10.8 million Euros, the sales in North America were 14% higher than those in the previous fiscal year (9.4 million Euros). The sales in Europe reached 11.9 million Euros (previous fiscal year: 11.8 million Euros). biolitec AG?s subsidiaries abroad, particularly in the Middle East and in Asia, delivered sales figures that showed gratifying growth rates of 37% (reaching 6.7 million Euros) as compared to the first three quarters of the previous year. biolitec?s medium-term goal is to increase the share of group revenue in these markets to one-third of sales.
The sales figure for the Meditec segment was 28.3 million Euros in the first three quarters, in the pharmaceuticals segment sales increased to nearly 1.1 million Euros.
biolitec has decided to publish its results for the first three quarters of 2011/12 even though the annual statement of accounts for 2010/11 has not yet been audited (the unaudited sales figure for which was 35.24 million Euros). The tentative sales figures for the 2011/12 fiscal year for the biolitec group are pegged at 40.27 million Euros.
In the meantime, biolitec has decided to relocate its registered office to Austria. In the course of the merger, the biolitec share shall be exchanged into new shares to the Entry Standard. Thus, continuous trading of the shares in the quality segment Entry Standard of the Frankfurt Stock Exchange shall be ensured for the shareholders. Dr. Neuberger, CEO of biolitec AG, states: ?The listing in the Entry Standard of the Frankfurt Stock Exchange requires less regulatory effort and saves costs for the company.?
To combine the transfer to Vienna with the already announced changeover to the Entry Standard, BioMed Technology Investment Holding as major shareholder with slightly more than 75% of the voting rights in biolitec AG has already announced to vote for the merger with biolitec AG?s Austrian subsidiary at the Extraordinary General Meeting of biolitec AG. The acceptance of a corresponding request is therefore ensured.
For the coming fiscal year 2012/13, biolitec expects growth to be sustained.
The information does not constitute an offer of or an invitation by or on behalf of biolitec AG or any of its subsidiaries to subscribe for or purchase securities of biolitec AG or any of its subsidiaries.
In particular, the information contained does not constitute an offer of securities for sale or solicitation of an offer to buy securities in the United States of America.
biolitec? AG is one of the leading companies worldwide in the field of medical laser treatments und the only provider that possesses all relevant core competencies ? photosensitizers, laser devices and optical fibres ? in the field of photodynamic therapy (PDT). Besides the laser treatment of cancer with Foscan?, biolitec? primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS Radial? (Endo Laser Vein System) the laser system is most often used worldwide for the treatment of varicose veins. Ceralas? HPD laser therapy enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in urology. Gentle laser treatments in the fields of proctology, ENT, orthopaedics, gynaecology as well as ophtalmology also belong to the business field of biolitec?. biolitec? is listed in the Prime Standard (ISIN DE0005213409). Further information at www.biolitec.de.
Kontakt:
biolitec AG
J?rn Gleisner
Otto-Schott-Stra?e 15
07745 Jena
+49 (0) 69/959083-20
info@biolitec.de
http://www.biolitec.de
Pressekontakt:
fr financial relations gmbh
J?rn Gleisner
Gutleutstr. 75
60329 Frankfurt
+49 (0) 69 / 959083-20
joern.gleisner@biolitec.com
http://www.biolitec.de
Related posts:
- biolitec AG continues on the growth path in the first half of 2011/12 by returning a group revenue of 19.36 million Euros ? EBIT declines to 0.9 million Euros Sales increase of 2.73 million compared to last year period ? Transfer of registered office to Austria planned ? Continued growth in the new fiscal year 2012/13 expected Jena, July 31st, 2012 ? biolitec AG (ISIN DE0005213409), Jena, listed on the Prime Standard of the Frankfurt Stock Exchange, achieved group sales of 19.36 million Euros [...]...
- biolitec supports Mouth Cancer Foundation for the 6th Mouth Cancer Walk in London More publicity for the fight against head and mouth cancer ? Photodynamic therapy is gaining ground ? Cancer drug Foscan? as a new option Jena, September 22, 2011 ? Employees of biolitec AG, leading provider of minimally invasive laser therapies and PDT (photodynamic therapy), took part in the 6th Mouth Cancer Walk in London, thus [...]...
- Breakthrough Medical Laser Innovations: biolitec? presents ELVeS Radial slim? and ELVeS Radial 2ring? Fibres for Varicose Vein Treatment Minimally-invasive varicose vein treatment further optimised through Radial? fibres by biolitec? ? Excellent characteristics, perfect positioning and maximum efficiency of the laser beam ? Treatment significantly more gentle ? Hundreds of thousands of patients already treated with ELVeS? Jena, February 7, 2012 ? www.biolitec.de ? With the development of the two novel fibres ELVeS Radial [...]...
- BHS-Sonthofen is investing seven million euros into its Sonthofen site A modern energy concept of the new administration building will save resources. On May 23, 2011, the foundation stone was laid at BHS-Sonthofen for the new administration building and a new warehouse was inaugurated. The new building will provide 90 employees with a modern working environment and will have enough spare capacity for further growth [...]...
- Nine-month results for 2011: DIC Asset AG exactly within the target range - Vacancy reduction is proceeding, year-end target of vacancy rate reduction to around 13 per cent will be realised - FFO with EUR 29.8 million well on track, target 2011 confirmed - Profit for the period of EUR 8.1 million according to plan - With acquisitions in excess of EUR 280 million, DIC Asset AG [...]...
Business related tags: biolitec, growth, sales figures
mars needs moms gary johnson gary johnson stephen curry hes just not that into you hes just not that into you texas longhorns
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.